BioSpace News Archive

Key Milestone Approaching with Testing Data Publication and Technology Advancement Results Expected this Quarter Cash Balance of $102 million or approximately $1.15 per share as of March 31st Positioned for Strategic Initiatives and Technology Development

Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Shaemus Gleason as Executive Vice President U.S. Operations as the company expands its presence, clinical trials, and operations in the U.S.

Eligibility for $0 out-of-pocket COVID-19 testing expanded to include adults and minors regardless of symptoms or suspected exposure, consistent with updated government guidance on insurance coverage for COVID-19 testing

SCIEX, a global leader in life science analytical technologies, announced an agreement with Waters Corporation to offer customers fully configured and interoperable Waters™ Ultra-Performance Liquid Chromatography (UPLC™) instruments as part of their purchase and deployment of SCIEX mass spectrometry (MS) systems.

Molecular Targeting Technologies, Inc. (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA ( 99m Tc-Duramycin), in patients with advanced colorectal cancer (CRC)*.

Neuroscientists at Northwell Health’s Institute for Neurology and Neurosurgery and The Feinstein Institutes for Medical Research will conduct a multi-centered, randomized, Phase 3 research study to learn if the experimental drug recombinant Factor Vlla (rFVllA), a protein that our body makes, can be used to decrease bleeding in the brain of patients who suffer sudden bleeding in the brain, also called intracerebral hemorrhage (ICH).

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today.

Annovis Bio CEO Maria Maccecchini, Ph.D. will deliver a corporate presentation at 3:10 p.m. ET on May 13, 2021.

Eyepic Eye Care an integrated eye care practice based in New York City, today announced a new revolutionary service to slow the progression of myopia in children – Myopic Control, using the only FDA-approved MiSight multifocal contact lenses.

OracleBio announced the launch of the company’s GCP Image Analysis Services.